Zentalis Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Zentalis Pharmaceuticals's estimated annual revenue is currently $46.3M per year.
- Zentalis Pharmaceuticals's estimated revenue per employee is $193,750
- Zentalis Pharmaceuticals's total funding is $517.1M.
Employee Data
- Zentalis Pharmaceuticals has 239 Employees.
- Zentalis Pharmaceuticals grew their employee count by 0% last year.
Zentalis Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, President and Director | Reveal Email/Phone |
2 | Senior Administrative Partner, Office the CEO | Reveal Email/Phone |
3 | Chief Business Officer | Reveal Email/Phone |
4 | Chief People Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Executive Assistant to Chief Medical Officer | Reveal Email/Phone |
7 | Chief Strategy Officer | Reveal Email/Phone |
8 | VP, Clinical Pharmacology | Reveal Email/Phone |
9 | VP, Data Management | Reveal Email/Phone |
10 | VP, Discovery Biology | Reveal Email/Phone |
Zentalis Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Zentalis Pharmaceuticals?
Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
keywords:N/A
$517.1M
Total Funding
239
Number of Employees
$46.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zentalis Pharmaceuticals News
Pfizer is throwing its weight behind Zentalis Pharmaceuticals' synthetic lethality candidate, making a $25 million investment in its new partner and...
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic...
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics...
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financing of Zentera Therapeutics, a biopharmaceutical company ...
NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the completion of an $85 million Series C fin ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $55.2M | 239 | -5% | N/A |
#2 | $15M | 239 | 0% | N/A |
#3 | $71M | 239 | 45% | N/A |
#4 | $52.7M | 239 | 23% | $4.5M |
#5 | $57.8M | 239 | 22% | N/A |